Audit: QRS - Vortioxetine for Health & Longevity

Audit conducted on 11/19/2026 14:50 using AI4L + evidence-mcp / Opus 5.5

Iterations

Summary

Items Count
Total 97
Passed 85
Failed 0
N/A 12
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Lede, gates, protocol, time cells, tiers, markers and cadence all trace to ER text (e.g., cadence matches ER lines 471-473; marker targets match the ER table)
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Hedges kept where the QRS carries them, e.g., “may need the upper dose range”, “possible added bleeding risk”, “remains unproven”
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No strengthening or softening found; contraindications mirror the ER’s “should avoid” list
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications come from “Populations who should avoid” plus the MAOI contraindication; modifying factors are not surfaced as gates or side effects
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, citations, expert names, NCT IDs or brand names appear

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢  
2.2 The tone of the QRS is expert, accessible, objective, and data-driven 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Protocol presented as label/EMA regimens, not instructions
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses the reader directly — it presents evidence, not guidance 🟢 No second-person address
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms are ER labels/headings carried verbatim (e.g., CYP2D6 inhibitors, hyponatremia) or necessary class names (MAOI); narrow angles and iridectomy rendered in plain words
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.10 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.11 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Lede closes on the healthy-aging question (“brain-sharpening value in healthy aging remains unproven”) and flags manufacturer funding
2.13 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No “anti-aging” wording
2.14 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 No colloquial route or adverse-event wording

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed headings, gate headings, tier labels and column headers match the template
3.2 Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name 🟢 All 40 template variables present; marker_# and qualitative_item_# expanded per 14.2/15.2
3.3 Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well 🟢 Diff against template shows changes only inside data-qrs-var spans and the metadata block

4. Formatting

# Description Result Comments
4.1 An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over. 🟢 No empty-state text; “Not specified in the ER” used only as 14.3 prescribes
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels, interaction labels and marker names match the ER bold labels / table entries
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Only example names trimmed from the serotonergic-drug label (“such as sertraline” etc.), which is permitted trimming
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji
4.5 The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit. 🟢 No trailing dash clauses, no optional glosses outside ER labels, example lists trimmed or required as qualifiers, no repetition

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration is quoted; it contains a colon
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 26.11.19 matches QRS.md
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 2026-1119-1354
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 Opus
5.9 The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 Opus 5.5
5.11 The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model 🟢  
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “Vortioxetine for Health & Longevity - Quick Reference Sheet”
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 11/19/2026
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Opus 5.5
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens with “a prescription antidepressant approved for adult major depression”
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses all three Conclusion paragraphs
7.3 [at_a_glance] is no longer than 70 words 🟢 68 words
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢  
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms or specialist terms
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢 All five ER avoid-populations present; MAOI and linezolid/methylene blue split into two items
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Explanations such as the anaphylaxis note and “in whom two trials showed no benefit” stripped
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 14-day and 21-day MAOI windows, age range 7-17 and “untreated”/”without an opening made in the iris” qualifiers kept
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 Section populated; ER names populations to avoid
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention --> N/A Section is not empty

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found 🟢 All nine documented interactions apart from MAOIs (contraindication) and alcohol/diazepam/lithium (no interaction) included
9.3 [caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label 🟢 All four theoretical interactions included
9.4 The ER placeholder “None identified” is never an item: it means that group is empty 🟢 No “None identified” item
9.5 Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause 🟢 No item carries “(theoretical)”, “inferred from” or a mechanism clause
9.6 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Trailing management notes (dose halving, monitoring, confirmatory testing) stripped
9.7 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug lists kept in the labels
9.8 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation
9.9 If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty. N/A ER theoretical group is not empty
9.10 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 Section populated
9.11 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. <!-- empty: ER names no interaction that changes how the intervention is used --> N/A Section is not empty

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Therapeutic Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from that section 🟢 Standard label regimen, European older-adult regimen and CYP2D6 limit
10.3 If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. N/A ER gives more than three aspects
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 6-8 weeks antidepressant, 8 weeks processing speed, about two weeks to steady levels (ER Practical Considerations)
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 High benefit first, Medium benefit second, pharmacokinetic timing last
11.3 If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. N/A ER gives three aspects
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty. N/A ER provides time-to-effect information

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Items are the ER benefit headings only
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parenthetical content
12.5 If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers have items

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Items are the ER risk headings only
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parenthetical content
13.5 If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers have items

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring Protocol & Defining Success section 🟢  
14.2 All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names 🟢 Serum sodium, PHQ-9, DSST, CYP2D6 genotype, INR and serum osmolality, each in its own numbered row
14.3 [marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER” 🟢 Targets match the ER table; INR and osmolality written “Not specified in the ER”
14.4 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty. 🟢 Cadence matches ER lines 471-473
14.5 If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template N/A ER names measurable biomarkers

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring Protocol & Defining Success section 🟢  
15.2 All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 … 🟢 All six ER qualitative markers listed verbatim
15.3 If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template N/A ER names qualitative markers

Issues 11/19/2026 14:50

Pass rate 100.00%. No issues found.

Issues 11/19/2026 14:49

  1. 9.6 / 4.5 — Management clauses in interactions: The Key Interactions items keep management elaborations after the key fact: “; vortioxetine dose halved” (line 562), “; after 14 days of co-use the dose may rise to at most three times the original” (line 563) and “; INR monitored with warfarin” (line 564). The INR clause also repeats the INR Monitoring row and cadence (lines 668-692).

Fixes 11/19/2026 14:49

  1. 9.6 / 4.5 — Management clauses removed: Stripped “; vortioxetine dose halved” from the Strong CYP2D6 inhibitors item, “; after 14 days of co-use the dose may rise to at most three times the original” from the Strong CYP inducers item, and “; INR monitored with warfarin” from the Antiplatelet/anticoagulant item, which also removes the INR repetition with the Monitoring card.

Issues 11/19/2026 14:45

  1. 4.5 — Optional glosses kept: The MAOI contraindication at line 548 carries “(monoamine oxidase inhibitor, a drug blocking a serotonin-degrading enzyme)” and the antiplatelet/anticoagulant interaction at line 564 carries “INR (a clotting test)”; both are optional glosses outside any ER label.

Fixes 11/19/2026 14:45

  1. 4.5 — Optional glosses removed: Removed the gloss “(monoamine oxidase inhibitor, a drug blocking a serotonin-degrading enzyme)” from the MAOI contraindication and “(a clotting test)” after INR in the antiplatelet/anticoagulant interaction.

Issues 11/19/2026 14:42

  1. 2.7 — Unexplained MAOI and INR jargon: The first Contraindication item (line 548) opens with the bare acronym “MAOI”, never expanded or glossed anywhere on the sheet, and the antiplatelet/anticoagulant interaction (line 564) uses “INR” without the ER’s gloss “a clotting test”.

Fixes 11/19/2026 14:42

  1. 2.7 — Glossed MAOI and INR: Expanded the first Contraindication item from “MAOI use” to “MAOI (monoamine oxidase inhibitor, a drug blocking a serotonin-degrading enzyme) use”, and changed “INR monitored with warfarin” to “INR (a clotting test) monitored with warfarin”, both using the ER’s own glosses.

Issues 11/19/2026 14:36

  1. 7.5 — Opaque drug-class shorthand: The at-a-glance text at line 439 ends its cost list with “serotonin-drug warnings”, a technical class shorthand a non-specialist cannot decode into the actual warnings (low blood sodium, bleeding, dangerous drug combinations).

Fixes 11/19/2026 14:36

  1. 7.5 — Opaque drug-class shorthand: Replaced “serotonin-drug warnings” in the at-a-glance text with “low-sodium, bleeding and drug-combination warnings”, trimming two other phrases to stay within 70 words.

Issues 11/19/2026 14:35

  1. 2.14 — Colloquial phrasing in lede: The at-a-glance text (line 439) says “dose-related sexual problems”, consumer-grade wording in the document’s own voice, instead of the formal term “sexual dysfunction” used by the ER’s risk label.

Fixes 11/19/2026 14:35

  1. 2.14 — Colloquial phrasing in lede: Replaced “dose-related sexual problems” with “dose-related sexual dysfunction” in the at-a-glance text.

Issues 11/19/2026 14:31

  1. 2.7 — Unexplained eye-anatomy jargon: The contraindication at line 552, “Untreated anatomically narrow angles without a patent iridectomy”, uses specialist terms the ER itself explains (“a tight eye drainage channel”, “an opening made in the iris”).

Fixes 11/19/2026 14:31

  1. 2.7 — Unexplained eye-anatomy jargon: Changed the contraindication from “Untreated anatomically narrow angles without a patent iridectomy” to “Untreated anatomically narrow eye drainage angles without an opening made in the iris”, using the ER’s own explanations.

Issues 11/19/2026 14:27

  1. 2.14 — Colloquial idiom in lede: The At-a-Glance text (line 439) ends with “Its value for keeping the brain sharp in healthy aging remains unproven”, using the lay idiom “keeping the brain sharp” in the document’s own voice instead of formal terminology.

Fixes 11/19/2026 14:27

  1. 2.14 — Colloquial idiom in lede: Replaced “keeping the brain sharp” with “preserving mental performance” in the At-a-Glance text (now 69 words).

Issues 11/19/2026 14:25

  1. 4.3 — Tier item labels paraphrased: Benefits Speculative at line 537 rewrites the ER labels “Synaptic Protection in Neurodegeneration Models” and “Anti-Glioblastoma Activity”, and Risks Low at line 602 renders the ER label “Hyponatremia” as “low blood sodium”.
  2. 4.5 — Optional glosses kept: “MAOI (monoamine oxidase inhibitor)” (line 548), “patent iridectomy (an opening made in the iris)” (line 552) and “INR (a clotting test)” (line 564) carry glosses that are not part of an ER bold label.
  3. 12.3 — Study detail in benefit: Benefits Speculative at line 537 adds “in Alzheimer’s-model mice”, a study detail absent from the ER item label.

Fixes 11/19/2026 14:25

  1. 4.3 / 12.3 — Speculative benefit labels restored: Replaced “Protection of nerve-cell connections in Alzheimer’s-model mice; activity against an aggressive brain cancer” with the ER labels “Synaptic protection in neurodegeneration models; anti-glioblastoma activity”, dropping the mouse-model study detail.
  2. 4.3 — Hyponatremia label restored: Replaced “low blood sodium” in Risks Low with the ER label “hyponatremia”.
  3. 4.5 — Optional glosses removed: Removed “(monoamine oxidase inhibitor)” after MAOI, “(an opening made in the iris)” after patent iridectomy, and “(a clotting test)” after INR.

Issues 11/19/2026 14:21

  1. 2.7 — Jargon in speculative benefits: The Speculative benefits item at line 537 reads “Synaptic protection in neurodegeneration models; anti-glioblastoma activity”, specialist jargon with no plain-language rendering, while the sheet renders other ER headings plainly (e.g., “Hyponatremia” as “low blood sodium”).

Fixes 11/19/2026 14:21

  1. 2.7 — Plain-language speculative benefits: Replaced “Synaptic protection in neurodegeneration models; anti-glioblastoma activity” with “Protection of nerve-cell connections in Alzheimer’s-model mice; activity against an aggressive brain cancer”, wording taken from the ER’s own glosses.

Issues 11/19/2026 14:17

  1. 4.5 — Repeated INR gloss in cadence: The Monitoring cadence at line 692 reads “clotting test (INR) with warfarin”, repeating the gloss already given by marker_5_why at line 674 (“Clotting check in people on warfarin”) in the same card.

Fixes 11/19/2026 14:17

  1. 4.5 — Repeated INR gloss in cadence: Changed “clotting test (INR) with warfarin” to “INR with warfarin” in monitoring_cadence, since marker_5_why already explains INR in the same card.

Issues 11/19/2026 14:14

  1. 14.3 — Osmolality purpose unclear: marker_6_why at line 685 reads “Paired with sodium if low”, which names a pairing rather than the purpose of serum osmolality and is ambiguous about what is low; the ER pairs osmolality (blood concentration) with sodium when sodium is low.

Fixes 11/19/2026 14:14

  1. 14.3 — Osmolality purpose clarified: Changed marker_6_why from “Paired with sodium if low” to “Blood concentration check when sodium is low”.

Issues 11/19/2026 14:10

  1. 7.2 — Evidence-quality caveat missing: The lede at line 439 presents the depression benefit without the ER Conclusion’s verdict that the evidence is “mostly produced by the companies that market the drug, and independent reviewers judged its quality low” (ER line 515).

Fixes 11/19/2026 14:10

  1. 7.2 — Evidence-quality caveat added: Added the ER Conclusion’s verdict to the lede (“though most evidence comes from its makers and independent reviewers judged its quality low”) and tightened other phrasing to stay at 70 words.

Issues 11/19/2026 14:06

  1. 4.5 — Repeated urine-screen context: The methadone item at line 569 restates its label “Methadone urine screens:” with “false-positive methadone results on standard urine screening tests”.
  2. 9.6 — Label attribution kept: The Strong CYP2D6 inhibitors item at line 562 ends with the attribution “the label halves the vortioxetine dose” instead of stating the dose fact alone.
  3. 14.2 — Serum osmolality marker missing: The ER Monitoring table (line 477) names serum osmolality as a measurable marker paired with sodium when low, but the QRS Monitoring table (lines 621-677) has no row for it.

Fixes 11/19/2026 14:06

  1. 4.5 — Repeated urine-screen context: Trimmed the methadone item from “false-positive methadone results on standard urine screening tests” to “false-positive methadone results”.
  2. 9.6 — Label attribution kept: Replaced “the label halves the vortioxetine dose” with “vortioxetine dose halved” in the Strong CYP2D6 inhibitors item.
  3. 14.2 — Serum osmolality marker missing: Added a sixth Monitoring row: Serum osmolality, target “Not specified in the ER”, why “Paired with sodium if low”.

Issues 11/19/2026 14:03

  1. 4.5 — Untrimmed serotonergic example list: The serotonergic-drugs label at line 561 keeps every “such as” example (sertraline, duloxetine, sumatriptan, amitriptyline) although the drug classes alone carry the gate.
  2. 7.2 — Lede omits class warnings: Line 439 says “The main costs are early nausea and dose-related sexual problems”, dropping the ER Conclusion’s third main cost, the warnings shared with other serotonin drugs (ER line 513).
  3. 14.2 — INR marker missing: The ER Monitoring section (ER line 471) names INR checks for warfarin users, but the Monitoring table (lines 621-666) has no INR row.

Fixes 11/19/2026 14:03

  1. 4.5 — Trimmed serotonergic example list: Dropped the “such as” example names (sertraline, duloxetine, sumatriptan, amitriptyline) from the serotonergic-drugs label, keeping every drug class and the ER’s in-label glosses.
  2. 7.2 — Added class warnings to lede: Changed “The main costs are early nausea and dose-related sexual problems” to “…early nausea, dose-related sexual problems and the warnings shared with other serotonin drugs” (68 words).
  3. 14.2 — Added INR marker row: Added marker_5 row “INR” / “Not specified in the ER” / “Clotting check in people on warfarin” to the Monitoring table.

Issues 11/19/2026 13:58

  1. 2.7 — Unexplained jargon in gates: “MAOI” (line 548), “patent iridectomy” (line 552) and “INR” (lines 564 and 670) appear without the plain-language gloss the ER provides.
  2. 4.5 / 11.4 — Repetitive time-to-effect sub: time_3_sub “Stable blood levels” (line 517) restates the label “Steady drug levels” (line 511) and adds no content.

Fixes 11/19/2026 13:58

  1. 2.7 — Glossed gate jargon: Added the ER’s glosses: “MAOI (monoamine oxidase inhibitor)”, “patent iridectomy (an opening made in the iris)”, “INR (a clotting test)” in the antiplatelet item, and “clotting test (INR)” in the cadence.
  2. 4.5 / 11.4 — Replaced repetitive sub: Changed time_3_sub from “Stable blood levels” to “66-hour half-life supports a single daily dose”, per the ER’s Therapeutic Protocol.

Issues 11/19/2026 13:55

  1. 2.7 — Clinical jargon in cadence: The monitoring cadence at line 670 says “INR with warfarin when vortioxetine is started, titrated or stopped”; “titrated” is unnecessary clinical jargon where the ER’s own “dose-adjusted” is available.
  2. 9.6 — Study detail retained: The Ketoconazole and fluconazole item at line 568 keeps the Chen 2013 exposure figures “(30% and 46%)”, a study detail that should be stripped to leave “modest increases in vortioxetine exposure”.

Fixes 11/19/2026 13:55

  1. 2.7 — Clinical jargon in cadence: Replaced “started, titrated or stopped” with the ER’s “started, dose-adjusted or stopped” in the monitoring cadence.
  2. 9.6 — Study detail retained: Removed the exposure figures “(30% and 46%)” from the Ketoconazole and fluconazole item, leaving “modest increases in vortioxetine exposure”.